A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
|Articles|March 18, 2019
Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer
Author(s)Charles Shapiro, MD
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.
Advertisement
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.
Advertisement
Related to this article
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.
Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
3
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
4
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
5